Cover Image

Effects of SGLT2 inhibition via empagliflozin on cognitive and physical impairment in frail diabetic elders with chronic kidney disease

Saved in:

Bibliographic Details
Main Authors:	Pasquale Mone (Author), Germano Guerra (Author), Angela Lombardi (Author), Maddalena Illario (Author), Antonella Pansini (Author), Anna Marro (Author), Salvatore Frullone (Author), Alessandro Taurino (Author), Daniela Sorriento (Author), Veronica Verri (Author), Guido Iaccarino (Author), Gaetano Santulli (Author)
Format:	Book
Published:	Elsevier, 2024-02-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

GRKs and β-Arrestins: "Gatekeepers" of Mitochondrial Function in the Failing Heart
by: Daniela Sorriento, et al.
Published: (2019)

The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury
by: Chang Chu, et al.
Published: (2019)

Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria
by: Yixiang Xu, et al.
Published: (2023)

Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
by: Joshua J Neumiller
Published: (2014)

Combining choline bitartrate and vitamin B12 ameliorates cognitive impairment in hypertensive elders with cognitive frailty
by: Pasquale Mone, et al.
Published: (2024)

The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile
by: Alana Aragón-Herrera, et al.
Published: (2022)

Reply to SGLT-2 inhibitors: Post-infarction interventional effects
by: Pasquale Paolisso, et al.
Published: (2023)

Effects of Sodium-Glucose Transporter 2 Inhibitors (SGLT2-I) in Patients With Ischemic Heart Disease (IHD) Treated by Coronary Artery Bypass Grafting via MiECC: Inflammatory Burden, and Clinical Outcomes at 5 Years of Follow-Up
by: Celestino Sardu, et al.
Published: (2021)

Clinical outcomes of a digitally supported approach for self-management of type 2 diabetes mellitus
by: Vincenzo De Luca, et al.
Published: (2023)

Effects of horticultural therapy: Perspectives of frail and pre‐frail older nursing home residents
by: Shirley K. L. Lo, et al.
Published: (2019)

Diet and Metabolic Dysfunction Clinical Evidence
by: Gaetano Santulli (Ed.)
Published: (2017)

Diet and Metabolic Dysfunction Evidence From Basic Research
by: Gaetano Santulli (Ed.)
Published: (2017)

Sport for All Frail Bodies
by: Jespersen Ejgil
Published: (2015)

Characterization of Frail Elderly and their Caretakers
by: Marina Selin Ganén, et al.
Published: (2012)

Caring for the frail, demented and dying
Published: (2010)

THE PHENOMENON OF POLUPHARMACY IN THE FRAIL ELDERLY
by: Carla Maria Silvano, et al.
Published: (2012)

THE PHENOMENON OF POLUPHARMACY IN THE FRAIL ELDERLY
by: Carla Maria Silvano, et al.
Published: (2012)

THE PHENOMENON OF POLUPHARMACY IN THE FRAIL ELDERLY
by: Carla Maria Silvano, et al.
Published: (2012)

THE PHENOMENON OF POLUPHARMACY IN THE FRAIL ELDERLY
by: Carla Maria Silvano, et al.
Published: (2012)

Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches
by: Yu Zhang, et al.
Published: (2023)

Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
by: Zofia Wicik, et al.
Published: (2022)

Empagliflozin in the treatment of type 2 diabetes: evidence to date
by: Shubrook JH, et al.
Published: (2015)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
by: Hilmi Alnsasra, et al.
Published: (2023)

Stability-indicating HPLC-DAD method for the determination of empagliflozin
by: Shilpi Pathak, et al.
Published: (2021)

Standards for the nursing care of the frail aged
by: L.R. Uys, et al.
Published: (1990)

Immunisation of older adults: where are the frail?
by: Jagadish K Chhetri
Published: (2017)

CARING FOR THE FRAIL AGED AND THEIR CAREGIVERS AT HOME
by: Lúcia H. T. Gonçalves, et al.
Published: (1996)

Beneficial effects of L-Arginine in patients hospitalized for COVID-19: New insights from a randomized clinical trial
by: Valentina Trimarco, et al.
Published: (2023)

Progress of patients hospitalized with acute heart failure treated with empagliflozin
by: Manuel Raya-Cruz, et al.
Published: (2024)

Empagliflozin Protects against Haloperidol Experimentally-Induced Ovarian Toxicity
by: Walaa Yehia Abdelzaher, et al.
Published: (2023)

The role of empagliflozin in the management of type 2 diabetes by patient profile
by: Hedrington MS, et al.
Published: (2015)

Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes
by: Munir KM, et al.
Published: (2016)

Empagliflozin-A New Chance for Patients with Chronic Heart Failure
by: Klaudia Kowalska, et al.
Published: (2021)

Use systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans
by: Yasong eLu, et al.
Published: (2014)

Handgrip strength and physical activity in frail elderly
by: Maria Helena Lenardt, et al.
Published: (2016)

The Importance of Physical Activity in Frail Elderly Individuals
by: Berker Can, et al.
Published: (2024)

Needs of frail elderly people in informal settlements
by: P du Rand, et al.
Published: (2001)

Effects of physical training on depression and related quality of life in pre-frail and frail older adults: a systematic review and meta-analysis
by: Wei-Han Weng, et al.
Published: (2024)

Effect of semaglutide and empagliflozin on cognitive function and hippocampal phosphoproteomic in obese mice
by: Xiaoyi Chen, et al.
Published: (2023)

Cost-effectiveness of empagliflozin for the treatment of heart failure: a systematic review
by: Jinyu Liu, et al.
Published: (2023)